The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 04, 2018

Filed:

Dec. 22, 2011
Applicants:

Salman M. Hyder, Columbia, MO (US);

Yayun Liang, Columbia, MO (US);

Xiaoqin Zou, Columbia, MO (US);

Sam Z. Grinter, Columbia, MO (US);

Sheng-you Huang, Columbia, MO (US);

Inventors:

Salman M. Hyder, Columbia, MO (US);

Yayun Liang, Columbia, MO (US);

Xiaoqin Zou, Columbia, MO (US);

Sam Z. Grinter, Columbia, MO (US);

Sheng-You Huang, Columbia, MO (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/452 (2006.01); A61K 31/135 (2006.01); A61K 31/138 (2006.01); A61K 31/343 (2006.01); A61K 31/381 (2006.01); A61K 31/416 (2006.01); A61K 31/423 (2006.01); A61K 31/428 (2006.01); A61K 31/44 (2006.01); A61K 31/4425 (2006.01); A61K 31/4439 (2006.01); A61K 31/536 (2006.01); A61K 31/5685 (2006.01); C12Q 1/26 (2006.01); C12Q 1/533 (2006.01); G01N 33/50 (2006.01); A61K 31/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/452 (2013.01); A61K 31/12 (2013.01); A61K 31/135 (2013.01); A61K 31/138 (2013.01); A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/416 (2013.01); A61K 31/423 (2013.01); A61K 31/428 (2013.01); A61K 31/44 (2013.01); A61K 31/4425 (2013.01); A61K 31/4439 (2013.01); A61K 31/536 (2013.01); A61K 31/5685 (2013.01); C12Q 1/26 (2013.01); C12Q 1/533 (2013.01); G01N 33/5011 (2013.01); G01N 2333/904 (2013.01); G01N 2333/99 (2013.01);
Abstract

Disclosed herein is a new and improved therapy for the treatment of cancer, which comprises the step of altering cell membrane lipid composition by treating a cancer cell with an enzyme inhibitor which inhibits enzymes regulating the cholesterol biosynthetic pathway. One preferred protein target in the cholesterol biosynthetic pathway to inhibit is oxidosqualene cyclase. In some forms, inhibitors of one or more pathways are combined with an existing chemotherapeutic agent to combat drug resistance and enhance the therapeutic efficacy of conventional therapy.


Find Patent Forward Citations

Hyder, Salman. (2018). Oxidosqualene cyclase as a protein target for anticancer therapeutics (U.S. Patent No. 10143686). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10143686

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…